A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
Mace L. Rothenberg(Vanderbilt University), Daniel D. Von Hoff(Translational Genomics Research Institute), M. Christine Cripps(The University of Texas at San Antonio Health Science Center), M.R. Green(University of California System), Anna Maria Storniolo(Indiana University Health), Russell K. Portenoy(Albert Einstein College of Medicine), John Sahl Andersen(The University of Texas at San Antonio Health Science Center), H.A. Burriss(Cancer Treatment Centers of America), E. S. Casper(Memorial Sloan Kettering Cancer Center), Malcolm J. Moore(University Health Network), T.D. Brown(Duke University), Peter G. Tarassoff(The University of Texas at San Antonio Health Science Center)
Cited by 569
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k